*Curriculum Vitae*

**Joyce S. Lee, MD MAS**

June 2022

Position: Associate Professor

 Division of Pulmonary Sciences and Critical Care Medicine

 Department of Medicine

 School of Medicine

Address: University of Colorado Denver

12631 E. 17th Avenue, C-323

Academic Office 1, Rm 7223

Aurora, CO 80045

Voice: (303) 724-6109

Cell: (650) 644-6512

Fax: (303) 724-6042

Email: Joyce.Lee@cuanschutz.edu

**EDUCATION and TRAINING:**

1996-1999 Northwestern University, Evanston, IL

 B.S. Medical Engineering

1999-2003 Northwestern University Feinberg School of Medicine, Chicago, IL

 M.D.

2003-2004 McGaw Medical Center of Northwestern University, Chicago, IL

 Intern, Internal Medicine

* 1. McGaw Medical Center of Northwestern University, Chicago, IL

Resident, Internal Medicine

Research Advisor: J. Iasha Sznajder, MD

* 1. University of California, San Francisco, Cardiovascular Research Institute, San Francisco, CA

Post-doctoral Fellow

 Research Advisor: Michael Matthay, MD

2007-2010 University of California San Francisco, San Francisco, CA

 Fellow, Pulmonary and Critical Care

 Research Advisor: Talmadge E. King, Jr., MD

2009-2011 University of California San Francisco, San Francisco, CA

 Master’s in Advanced Studies, Clinical Research Degree Program

**PRINCIPAL POSITIONS HELD:**

2010-2012 Clinical Instructor, Department of Medicine, University of California, San Francisco

2012-2013 Adjunct Assistant Professor, Department of Medicine, University of California, San Francisco

2013-2015 Assistant Professor, Clinical X Series, Department of Medicine, University of

 California, San Francisco

2015-2018 Assistant Professor, Department of Medicine, University of Colorado Denver

2018-present Associate Professor, Department of Medicine, University of Colorado Denver

**OTHER POSITIONS HELD CONCURRENTLY:**

2012-2015 Director, UCSF Interstitial Lung Disease Clinic, San Francisco, CA

2016-2019 Medical Director, Advanced Lung Disease Clinic, Center for Lungs and Breathing, University of Colorado Hospital, Aurora, CO

2016-present Director, University of Colorado Denver Interstitial Lung Disease Program, Aurora, CO

2018-present Program Director, Advanced Pulmonary Fellowship Training in Interstitial Lung Disease, University of Colorado School of Medicine, Aurora, CO

2020-present Senior Medical Advisor, Pulmonary Fibrosis Foundation, Chicago, IL

**HONORS AND AWARDS:**

1997 Tau Beta Pi Engineering Honor Society

1999 James A. Patten Award - Merit scholarship based on the highest academic achievement for incoming members of the Honors Program in Medical Education

2001 Summa Cum Laude graduate, Northwestern University

2003 Department of Medicine, Excellence in Teaching Award (8/2003,

 10/2003)

2004 Department of Medicine, Excellence in Teaching Award (8/2004,

 11/2004)

2005 Co-Captain and recipient of Sir William Osler Cup National Medical

Jeopardy Champion, American College of Physicians Annual Meeting,

April 2005, San Francisco, CA

2006 Northwestern University Resident Research Symposium, recipient of Best

 Resident Presentation in Basic Science

2009 Individual Ruth L. Kirschtein National Research Service Award (NRSA)

2011 Walter Travel Fund Recipient

2012 UCSF Clinical and Translational Sciences Institute (CTSI) KL2 Scholar

2012 The 17th International Colloquium on Lung and Airway Fibrosis Young

 Investigator Award, Modena, Italy

**PROFESSIONAL ORGANIZATIONS:**

2007-present American Thoracic Society, member

2009-2010 California Thoracic Society, member

2012-present American College of Chest Physicians, member

2018-present European Respiratory Society, member

**MAJOR COMMITTEE AND SERVICE RESPONSIBILITIES:**

**International/National Service and Leadership**

2022-2023 Chair, Clinical Problems Assembly Program Committee, American Thoracic Society

2021-2022 Chair-Elect, Clinical Problems Assembly Program Committee, American Thoracic Society

2020-2021 Elected member, Nominating Committee Clinical Problems Assembly, American Thoracic Society

2019-present Member, Benchmarking Committee, Pulmonary Fibrosis Foundation

2018-present Mentor, Clinical Problems Assembly, American Thoracic Society

2017-2020 Co-chair, Clinical Year In Review (CYIR) program committee, American Thoracic Society Conference (2018-2020)

2017 Selected to participate in the NIH/NHLBI/ORWH workshop on “Female Sex and Gender in Lung/Sleep Health and Disease”, September 2017

2017-2018 Co-chair, Program Committee, International Colloquium on Lung and

 Airway Fibrosis Conference 2018

**Local Service and Leadership**

2020-present Member, Scientific Advisory Committee for the Pulmonary Sciences and Critical Care Medicine Division, University of Colorado Denver

2019-2020 Co-chair, Excellence Seminar Series, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver

2018-2021 Executive Committee Member, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver

2017-2018 Appointment and Promotion Committee Member, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver

2017 Co-chair Divisional Task Force, Division of Pulmonary Sciences and

Critical Care Medicine, University of Colorado Denver

2017-2019 Steering Committee Member, University of Colorado, Center for Lungs and Breathing annual CME event

2016-present Pillar Leader, Advanced Lung Disease, University of Colorado Hospital,

 Center for Lungs and Breathing

2015-present Fellowship Applicant Interviewer, University of Colorado Denver, Aurora,

CO

**Service to International Guideline Development and Working Groups**

2019 ATS research statement on patient centered outcomes in interstitial lung disease, member

2019 ATS/ERS task force on combined pulmonary fibrosis and emphysema, writing group member

2017 Connective tissue disease ILD summit, panelist

2017 A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An

International Working Group Perspective. Writing group member

2016 Acute Exacerbation of Idiopathic Pulmonary Fibrosis: An International

Working Group Report. Writing group leader.

2015 ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD. An official

 European Respiratory Society/American Thoracic Society research

 statement: interstitial pneumonia with autoimmune features. Writing group

 member.

**Leadership Courses**

2020 University of Colorado Denver, Department of Medicine Program to Advance

Gender Equity (PAGE), Selection and Participation

2018 University of Colorado Denver, CCTSI Leadership for Innovative Team

 Science (LITeS) program, Selection and Participation

2016 University of Colorado Denver, Women’s Leadership Training Course,

 Selection and Participation

2016 University of Colorado Denver, Department of Medicine Junior Faculty

 Mentor Program (JUMP), Selection and Participation

2016 University of Colorado Denver, Clinical Leadership Development Program,

 Academy of Medical Educators (AME) and the Institute for Healthcare

 Quality, Safety and Efficiency (IHQSE), Selection and Participation

2011 UCSF Scientific Leadership and Management Course, Selection and

 Participation

**LICENSES AND BOARD CERTIFICATION:**

2006 Medical licensure, California

2006 American Board of Internal Medicine

2009 Pulmonary Boards

2010 Critical Care Medicine Boards

2011 Fluoroscopy X-Ray Supervisor and Operator

2015 Medical licensure, Colorado

**REVIEW AND REFEREE WORK:**

2011-present Ad Hoc Peer Review; CHEST

2012-present Ad Hoc Peer Review; Respiratory Medicine

2012-present Ad Hoc Peer Review; Proceedings of the American Thoracic Society

2013-present Ad Hoc Peer Review; Thorax

2013-present Ad Hoc Peer Review; European Respiratory Journal

2013-present Ad Hoc Peer Review; American Journal of Respiratory and Critical Care

 Medicine

2015-present Abstract reviewer, Clinical Problems Assembly, American Thoracic

 Society

2018-present Ad Hoc Peer Review; New England Journal of Medicine

2021-present Editorial board for diffuse lung disease; CHEST

**INVITED EXTRAMURAL LECTURE/PRESENTATIONS:**

**Invited Presentations (International/National):**

2022 Oporto ILD meeting, Invited International Speaker. Rheumatoid Arthritis associated ILD and IPF: two sides of the same coin? Virtual meeting. Lisbon, Portugal

2021 European Respiratory Society, Invited International Speaker. Academy on ILD: Get the basics right: why do acute exacerbations develop in interstitial lung disease. Virtual meeting. Heidelberg, Germany.

2021 Pulmonary Fibrosis Foundation, Invited Speaker. ILD Day: Overview of Interstitial Lung Disease. Virtual webinar. Chicago, IL.

2021 American Thoracic Society, Co-Chair, Fibrosing Interstitial Lung Disease. Virtual meeting.

2021 University of Kansas, Medical Grand Grounds, More than just alphabet

soup… Advances in our understanding of interstitial lung disease. Virtual.

Kansas City, Missouri.

2020 American Thoracic Society, Mythbuster oral presentation, Novel single cell profiling technologies will have a significant impact on the understanding and management of pulmonary fibrosis. Virtual meeting.

2019 British Thoracic Society annual meeting, Invited International Speaker, Plenary Session. IPF and RA-ILD: is there a connection? London, UK.

2019 Pulmonary Fibrosis Foundation PFF Summit Meeting, Faculty Speaker, What is Pulmonary Fibrosis? San Antonio, Texas.

2019 American Thoracic Society, Oral Presentation, Clinical Year in Review: Interstitial Lung Disease, Dallas, TX

2019 Thoracic Society of Australia and New Zealand (TSANZ) annual meeting, Invited International Speaker, Plenary Session. Meet the Experts and Acute exacerbations in IPF – diagnosis and management. Gold Coast, Australia

2019 Thoracic Society of Australia and New Zealand (TSANZ) annual meeting, Invited International Speaker, Post-Graduate Course. Mock ILD MDT and IPF update 2: Drug Treatment. Gold Coast, Australia

2018 International Colloquium on Lung and Airway Fibrosis, Invited International Speaker, Plenary Session, IPF and RAILD: Is there a connection? Monterey, CA

2018 European Respiratory Society, Oral Presentation, Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis. Paris, France

2018 Pulmonary Fibrosis Foundation, Patient webinar, Faculty Speaker

2017 Pulmonary Fibrosis Foundation PFF Summit Meeting, Invited Faculty Speaker, Overview of pirfenidone and nintedanib, Nashville, TN

2017 Pulmonary Manifestations of Connective Tissue Disorders 2017, Invited Faculty Speaker, Approach to the Patient with Interstitial Lung Disease Associated with a Connective Tissue Disease, Amelia Island, FL

2017 NIH Workshop on Female Sex and Gender in Lung/Sleep Health and Disease: Increased understanding of basic biological, pathophysiological and behavioral mechanisms leading to better health for female patients with lung disease, Invited speaker, Impact of sex/gender on the clinical management of fibrotic lung disease, Washington D.C.

2017 European Respiratory Society, Invited International Speaker, Plenary Session Scientific Grand Rounds: Systemic autoimmunity and pulmonary fibrosis. Milan, Italy

2017 Diffuse Lung Disease Conference, Invited International Speaker, Mumbai, India

2017 American Thoracic Society, Mini-Symposium Co-Chair, IPF: Moving Forward. Washington D.C.

2017 American Thoracic Society, Meet the Professor Seminar, Cross-Disciplinary Evaluation and Management of CTD-ILD. Washington D.C.

2017 American Thoracic Society, Scientific Symposium Co-Chair, A Multidisciplinary, Case-Based Approach to Hot Topics in CTD-ILD. Washington, D.C.

2016 American College of Rheumatology, Invited Faculty Speaker, ACR Clinical Research Conference: RA Lung – Future Research Initiatives in RA-ILD. Washington D.C.

2016 American College of Rheumatology, Session Co-Chair, ACR Clinical Research Conference: RA Lung, Washington D.C.

2016 American College of Chest Physicians, Invited Faculty Speaker, Detection and Management of GERD in IPF. Los Angeles, CA

2016 American College of Chest Physicians, Invited Faculty Speaker, Gastroesophageal Reflux Disease and IPF. Los Angeles, CA

2016 American Association for Respiratory Care Congress, Faculty Speaker, The Spectrum of IPF. San Antonio, TX.

2016 American Association for Respiratory Care Congress, Faculty Speaker, Changing Treatment Paradigms for IPF. San Antonio, TX.

2016 American Thoracic Society, Scientific Symposium Speaker, Non-IPF ILD: How Do I Make the Diagnosis? San Francisco, CA

2016 American Thoracic Society, Scientific Symposium Co-Chair, The Road to Precision Medicine in IPF: Biomarkers and Clinical Predictors. San Francisco, CA

2016 American Thoracic Society, Post-graduate course speaker, Resident Boot Camp: How To Teach in Small Groups. San Francisco, CA

2016 Comprehensive Care and Management of Comorbidities in Patients with ILD, Centre hospitalier de l’Universite de Montreal (CHUM), Pulmonary CME, Invited International Speaker, Montreal, Quebec, Canada

2016 Pulmonary Fibrosis Foundation, Patient webinar, Faculty Speaker

2015 Pulmonary Fibrosis Foundation PFF Summit Meeting, Faculty Speaker, What is Pulmonary Fibrosis and Why is it a Problem? Washington, D.C.

2015 Pulmonary Fibrosis Foundation PFF Summit Meeting, Session Co-Chair, Pulmonary Fibrosis: What and Why. Washington, D.C.

2015 American Thoracic Society, Mini-Symposium Co-Chair, We Can Work it Out: Diagnosing and Differentiating Interstitial Lung Disease. Denver, CO

2015 American Thoracic Society, Post-graduate Course Speaker, Management of Co-morbidities in Idiopathic Pulmonary Fibrosis. Denver, CO

2015 American Thoracic Society, Scientific Symposium Co-Chair, Common Clinical Dilemmas in Connective Tissue Disease-Associated ILD. Denver, CO

2015 American Thoracic Society, Scientific Symposium Speaker, High Yield Clinical Updates in CTD-ILD: Rheumatoid Arthritis and Interstitial Pneumonia with Autoimmune Features. Denver, CO

2014 American Thoracic Society, Scientific Symposium Co-Chair, The Evolving Role of Genetics in the Clinical Care of Patients with Pulmonary Fibrosis. San Diego, CA

2014 The 18th International Colloquium on Lung and Airway Fibrosis, Invited International Speaker, Plenary Session, GERD & IPF: is there much beyond association? Mont Tremblant, Quebec, Canada

2013 Pulmonary Fibrosis Foundation IPF Summit Meeting, Faculty Speaker, GERD and Microaspiration in IPF: Fundoplication for Everyone? La Jolla, CA

2013 American Thoracic Society, Scientific Symposium Speaker, The Relationship Between Gastroesophageal Reflux and IPF. Philadelphia, PA

2013 American Thoracic Society, Scientific Symposium Co-Chair, The Evolving Role of Gastroesophageal Reflux Disease and Aspiration in Parenchymal Lung Disease. Philadelphia, PA

2013 American Thoracic Society, Oral Presentation, Telomere length, disease severity, and survival in IPF. Philadelphia, PA

2012 American College of Chest Physicians, Featured Lecturer for the Interstitial and Diffuse Lung Disease Network Steering Committee, The Relationship Between Gastroesophageal Reflux and IPF. Atlanta, GA

2012 American College of Chest Physicians, Faculty Speaker, Reflux and Microaspiration in IPF: Does it have a role in pathogenesis. Atlanta, GA

2012 The 17th International Colloquium on Lung and Airway Fibrosis, Oral Presentation, Telomere length, disease severity, and survival in IPF. Modena, Italy

2011 American Thoracic Society, Sunrise Seminar: Thematic Seminar Series,

Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis, Denver, CO

2010 The 16th International Colloquium on Lung and Airway Fibrosis, Poster

 Presentation, Busselton, Western Australia, Australia

**Invited Presentations (Local):**

2021 Comprehensive Lungs and Breathing Summit, Invited speaker, Updates in the Management of Interstitial Lung Disease, Virtual

2021 Early Interstitial Lung Disease in Rheumatoid Arthritis, Clinical and Translational Research Seminar, National Jewish Health, Denver, CO

2020 Comprehensive Lungs and Breathing Summit, Invited speaker, Update in Interstitial Lung Disease Clinical Trials, Virtual

2020 Medical Grand Rounds, University of Colorado, More than just alphabet soup… Advances in our understanding of interstitial lung disease. Aurora, CO

2020 Genetics in Rheumatoid Arthritis associated Interstitial Lung Disease,

Clinical and Translational Research Seminar, National Jewish Health,

Denver, CO

2019 Comprehensive Lungs and Breathing Summit, Invited speaker, Update in Interstitial Lung Disease, Colorado Springs, CO

2018 Comprehensive Lungs and Breathing Summit, Invited speaker, Multidisciplinary Approach to ILD, Colorado Springs, CO

2018 Updates in Interstitial Lung Disease, CME Grand Rounds, Pomona Valley Hospital Medical Center, Pomona, CA

2018 Updates in Interstitial Lung Disease, CME Grand Rounds, Mercy Hospital Ft. Smith, Ft. Smith, AR

2017 Comprehensive Lungs and Breathing Summit, Invited speaker, Updates in Interstitial Lung Disease, Colorado Springs, CO

2017 Division Fellowship Retreat, Invited speaker, My Career Path: some personal reflections, Breckenridge, CO

2017 Lung Fibrosis and Regeneration Science Day, Co-Chair and Speaker, RA patients at risk for interstitial lung disease, Aurora, CO

2017 Patient Support Group, Invited speaker, What is pulmonary fibrosis and why is it a problem? Aurora, CO

2016 More Than Just Alphabet Soup: Similarities Between IPF and RA-ILD.

Rheumatology Grand Rounds, University of Colorado Denver, Aurora,

CO

2016 Updates in Interstitial Lung Disease. Medicine Grand Rounds, Good Samaritan Hospital, Lafayette, CO

2015 Risk Prediction in Scleroderma Related Interstitial Lung Disease, Clinical

 and Translational Research Seminar, National Jewish Health, Denver,

 CO

2014 Co-morbidities in idiopathic pulmonary fibrosis, CME, San Francisco, CA

2013 Connective Tissue Diseases and the Lung. Medicine Grand Rounds, San

Francisco General Hospital, San Francisco, CA

2013 Update on Interstitial Lung Disease. Medicine Grand Rounds, Veterans

Administration Hospital, San Francisco, CA

2013 Update on Interstitial Lung Disease. Medicine Grand Rounds, Kaiser Hospital, Oakland, CA

2013 Connective Tissue Diseases and the Lung. Medicine Grand Rounds,

 University of California, San Francisco, San Francisco, CA

2012 Connective Tissue Disease associated ILD. CME, San Francisco, CA

2012 Overview of Interstitial Lung Disease, UCSF Department of Medicine

 Noon Conference, San Francisco, CA

2012 A Review of Interstitial Lung Disease. Medicine Grand Rounds, Highland

 Hospital, Oakland, CA

2011 Review of Interstitial Lung Disease. Advances in Internal Medicine CME,

 San Francisco, CA

2011 Overview of Interstitial Lung Disease. UCSF Department of Medicine

 Noon Conference, San Francisco, CA

2011 Gastroesophageal Reflux Therapy in Idiopathic Pulmonary Fibrosis.

 UCSF Pulmonary Division Tri-hospital Research Conference, San

 Francisco, CA

2010 Reflux and Microaspiration in IPF. UCSF Pulmonary Division Tri-Hospital Research Conference, San Francisco, CA

2010 Case presentation. California Thoracic Society, Carmel, CA

2009 Sepsis: Are we winning the battle? Grand Rounds, UCSF Pulmonary

 Division, San Francisco, CA

2008 Air Travel in Patients with Lung Disease. Pulmonary Physiology

 Conference, UCSF Pulmonary Division, San Francisco, CA

2007 Nontuberculous Mycobacterial Lung Diseases. Grand Rounds, UCSF Pulmonary Division, San Francisco, CA

2006 Clinicopathologic Conference (case: Lymphocytic Interstitial Pneumonia in Systemic Lupus Erythematosus with Secondary Sjogren’s syndrome),

 Northwestern University, Chicago IL

2005 “Doc, I’m short of breath.” An Approach to Interstitial Lung Disease.

Internal Medicine Conference, Northwestern University, Chicago IL

**TEACHING:**

**Presentations to trainees**

2019 Advanced Practice Providers: Hospitalized patient with interstitial lung disease, 60 minute lecture, 8-10 APPs

2018 Pulmonary Fellows Educational Series: Diagnosis and Management of IPF, 60 minute lecture, 18 fellows

2017 CU Clinical Cardiovascular, Pulmonary, and Renal (CVPR) lecture: Diseases of the Mediastinum and Pleura, 1 hour, 1st year medical students

2017 Pulmonary Fellows lecture, pre-clinic lecture on approach to interstitial

lung disease, 45-minute didactic session, 12 fellows

2016 Pulmonary Fellows Educational Series: Interstitial Lung Disease, 90 minute lecture, 18 fellows

2016 CU Clinical Cardiovascular, Pulmonary, and Renal (CVPR) lecture: Diseases of the Mediastinum and Pleura, 1 hour, 1st year medical students

2015 Internal Medicine Resident Conference, UCSF, 1 hour, 20 residents

2015 Graduate Education in Medical Science course, UCSF, 1 hour lecture, 50

 post-graduate students

2014 Internal Medicine Resident Conference, UCSF, 1 hour, 20 residents

2014 Graduate Education in Medical Science course, UCSF, 1 hour lecture, 50

 post-graduate students

2013 Internal Medicine Resident Conference, UCSF, 1 hour, 20 residents

2013 Graduate Education in Medical Science course, UCSF, 1 hour lecture, 50

post-graduate students

2012 Internal Medicine Resident Conference, UCSF, 1 hour, 20 residents

2012 Graduate Education in Medical Science course, UCSF, 1 hour lecture, 50

 post-graduate students

2011 Internal Medicine Resident Conference, UCSF, 1 hour, 20 residents

2010 UCSF Pulmonary Small Groups Section Leader, 6 hours, 15 2nd year

 medical students

2008 Summer Lecture Series, UCSF, 1 hour, 7 1st year pulmonary fellows

**Ward and clinic attending duties**

2017-present Comprehensive Lungs and Breathing Interstitial Lung Disease Clinic Attending (2 four hour clinics weekly, supervision and bedside teaching of pulmonary fellows)

2016-2020 Advanced Lung Disease Clinic Attending (2 four hour clinics per

 semester, supervision and bedside teaching of pulmonary fellows)

2015-2017 Attending rounds, Advanced Lung Service, University of Colorado

 Hospital (4-6 weeks/year)

2012-2015 UCSF Interstitial Lung Disease Clinic Attending (4 hours weekly)

2012-2015 ILD Discussant at Internal Medicine M&M Case Conference (1 hour

 conference 2-3 times per year)

2012-2015 San Francisco VA ILD Conference Discussant (2 hours every other

 month)

2012 Attending rounds, Pulmonary Consult Service, UCSF Moffitt Hospital

2011-2012 Attending, Night Hospitalist Service – teaching and supervising interns

and residents, UCSF Moffitt Hospital (1 night/week)

2011-2015 Attending rounds, Lung Transplant service, UCSF (6 weeks/year)

**Teaching awards**

2003 Department of Medicine, Excellence in Teaching Award (8/2003,

 10/2003)

2004 Department of Medicine, Excellence in Teaching Award (8/2004,

 11/2004)

**RESEARCH:**

**Grant support**

*Current*

7/2017-6/2021 (NCE) W81XWH-17-1-0597 (PI: David Schwartz)

DOD

Idiopathic Pulmonary Fibrosis, a Disease Initiated by Mucociliary Dysfunction

This is a program project grant that will improve our understanding of the *MUC5B* promoter variant and mucin biology in IPF in order to develop the scientific basis to predict, detect, and prevent the progression of preclinical pulmonary fibrosis.

Role: Co-investigator

8/1/2020 – 7/31/2022 UG3 HL 151865 (PI: David Schwartz)

NIH/NHLBI

Preclinical Pulmonary Fibrosis, an opportune rare disease cohort

The goal of this UG3 is to develop a cohort of subjects at risk for pulmonary fibrosis due to their genetics and family history of disease.

Role: Co-investigator

8/1/2019-7/31/2021 (NCE) AWARD: 18-1808 (PI)

Boehringer Ingelheim Investigator Initiated Study

Novel Biomarkers in Rheumatoid Arthritis Associated Interstitial Lung Disease

The goal of this study is to obtain bronchoalveolar lavage and peripheral blood in RA and RA-ILD to identify novel biomarkers of disease.

Role: PI

09/01/2021-9/30/2022     25B1472 (PI: Demoruelle)

Boehringer Ingelheim Investigator Initiated Study

The Lung Microbiome and Lung Metabolome in RA-Related ILD

The goals of the project are to establish lung microbiota and metabolomic profiles in sputum that are associated with RA-ILD.

Role: Co-investigator

04/01/22 - 03/30/27 R01 HL158668 (MPIs: Schwartz [contact], Yang)

NIH-NHLBI

Molecular Determinants of Usual Interstitial Pneumonia

The overall goal of this proposal is to understand how the gain-of-function *MUC5B* promoter variant affects transcriptional regulation and gene expression in clinically distinct types of usual interstitial pneumonia.

Role: co-investigator

*Clinical Trials*

3/29/2018 – present                                       SLS III (PI: Mike Roth)

UCLA and Genentech

Scleroderma Lung Study III (SLS 3): Combining the anti‐fibrotic effects of pirfenidone (PFD) with mycophenolate (MMF) for treating scleroderma related interstitial lung disease

Role: Site PI (Sub-I prior to Aug 9, 2019)

11/15/2017 – present                                     1199.225

Boehringer-Ingelheim

An open-label extension trial to assess the long-term safety of nintedanib in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’ (SSc-ILD)

Role: Site PI (Sub-I prior to Aug 9, 2019)

4/30/2020-present FGCL-3019-091

FibroGen, Inc

A Phase 3, Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study of Pamrevlumab in Subjects with Idiopathic Pulmonary Fibrosis.

Role: Site PI

*Past Grant Support and Clinical Trials*

9/2009 – 6/2012 NIH, F32 HL097383 (PI)

The Role of Microaspiration in IPF

6/2009 – 5/2011 REAC Grant Award (PI: Harold Collard)

University of California San Francisco

The Role of Microaspiration in Idiopathic Pulmonary Fibrosis

Support a pilot study of microaspiration in patients with IPF.

Role: Co-investigator

7/2012 – 6/2016 NIH/NCRR/OD UCSF-CTSI KL2 RR024130

U8 KL2 TR000143-07 (Johnston)

NCATS

Clinical and Translational Science Institute (CTSI)

The goal of the CTSI KL2 career development award is to increase the number and quality of clinical and translational investigators skilled at leading multidisciplinary research teams.

My role is as a KL2 Scholar, for which I receive salary support for 9 calendar months, plus research funds.

2/2013-1/2014 REAC Grant Award (PI)

University of California San Francisco

Usual interstitial pneumonia pattern: comparison of rheumatoid arthritis and idiopathic pulmonary fibrosis

Support a pilot study of understanding the biologic relationship between rheumatoid arthritis associated interstitial lung disease and idiopathic pulmonary fibrosis.

8/2013 – 7/2016 1R43HL120427-01 (PI: Homer Boushey, Igor Gonda)

NIH/NHLBI

Development and Validation of test for Gastro-esophageal Reflux with Aspiration

This is a small business innovation research grant to investigate a diagnostic test for gastroesophageal reflux related aspiration.

Role: Co-investigator

8/2013 – 5/2016 UM1HL119089 (PI: Harold Collard, Ganesh Raghu)

NIH/NHLBI

Treatment of IPF with laparoscopic anti-reflux surgery.

This is a phase-2 study investigating the intervention of laparoscopic anti-reflux surgery in patients with IPF.

Role: Co-investigator

8/2017-7/2020 K23 HL138131 (PI)

NIH/NLBI

Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease.

This is a prospective study of rheumatoid arthritis patients looking at the clinical, genetic and biologic features of patients with and without subclinical interstitial lung disease.

Mentor: David A. Schwartz, MD, Co-mentor: Michael Holers, MD

2/23/2016 – 2/13/2019                                   1199.214

Boehringer-Ingelheim

A double blind, randomised, placebo-controlled trial evaluating efficacy and safety of oral nintedanib treatment for at least 52 weeks in patients with ‘Systemic Sclerosis associated Interstitial Lung Disease’(SSc-ILD).

Role: Sub-I

11/30/2017 – 8/9/2019                                   ATtackMy-ILD (PI: Rohit Aggarwal)

UPitt and Bristol Myers Squibb

A randomized, controlled pilot trial to evaluate the efficacy and safety of subcutaneous Abatacept in treating interstitial lung disease associated with the anti-synthetase syndrome

Role: Sub-I

2/7/2019-6/21/2020 BI 1199-0324

Boehringer Ingelheim Pharmaceuticals

Study of Pulmonary Rehabilitation in Nintedanib Treated Patients with IPF: Improvements in Activity, Exercise Endurance, Time and QoL

Role: Site PI

5/16/2018-8/19/2021 VAY736X2207

Novartis Pharmaceuticals Corporation

A subject-, investigator-, and sponsor-blinded, randomized placebo-controlled multicenter study to investigate the efficacy, safety and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis.

Role: Site PI

8/21/2019-close out in process GLPG1690-CL-303

Galapagos NV

A Phase 3, randomized, double-blind, parallel-group, placebo-controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

Role: Site PI

5/15/2020-close out in process BMS IM027-040

Bristol Meyers Squibb

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-982678 in Participants with Pulmonary Fibrosis

Role: Site PI

**BIBLIOGRAPHY:**

**Complete List of Published Work in MyBibliography:**

http://www.ncbi.nlm.nih.gov/sites/myncbi/1Dkuy9vU7g5Q7/bibliography/40453685/public/?sort=date&direction=ascending

**Original Research Papers (chronological order):**

1. Kim EJ, Elicker BM, Maldonado F, Webb WR, Ryu JH, Van Uden JH, **Lee JS,** King TE, Jr., Collard HR. Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2010;35(6):1322-8. doi: 10.1183/09031936.00092309. PubMed PMID: 19996193.

2. Comellas AP, Kelly AM, Trejo HE, Briva A, **Lee J,** Sznajder JI, Dada LA. Insulin regulates alveolar epithelial function by inducing Na+/K+-ATPase translocation to the plasma membrane in a process mediated by the action of Akt. J Cell Sci. 2010;123(Pt 8):1343-51. doi: 10.1242/jcs.066464. PubMed PMID: 20332111; PMCID: PMC2848117.

3. **Lee JS,** Su X, Rackley C, Matthay MA, Gupta N. Priming with endotoxin increases acute lung injury in mice by enhancing the severity of lung endothelial injury. Anat Rec (Hoboken). 2011;294(1):165-72. doi: 10.1002/ar.21244. PubMed PMID: 21157927; PMCID: PMC3072226.

4. Wootton SC, Kim DS, Kondoh Y, Chen E, **Lee JS,** Song JW, Huh JW, Taniguchi H, Chiu C, Boushey H, Lancaster LH, Wolters PJ, DeRisi J, Ganem D, Collard HR. Viral infection in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(12):1698-702. doi: 10.1164/rccm.201010-1752OC. PubMed PMID: 21471095; PMCID: PMC3136996.

5. **Lee JS,** Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, King TE, Jr., Collard HR. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390-4. doi: 10.1164/rccm.201101-0138OC. PubMed PMID: 21700909; PMCID: PMC3262030.

6. **Lee JS,** Song JW, Wolters PJ, Elicker BM, King TE, Jr., Kim DS, Collard HR. Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J. 2012;39(2):352-8. doi: 10.1183/09031936.00050911. PubMed PMID: 22183478; PMCID: PMC5529033.

7. Richeldi L, Ryerson CJ, **Lee JS,** Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Jr., Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012;67(5):407-11. doi: 10.1136/thoraxjnl-2011-201184. PubMed PMID: 22426899.

8. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, **Lee JS,** Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Jr., Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684-91. doi: 10.7326/0003-4819-156-10-201205150-00004. PubMed PMID: 22586007.

9. Cha SI, Ryerson CJ, **Lee JS,** Kukreja J, Barry SS, Jones KD, Elicker BM, Kim DS, Papa FR, Collard HR, Wolters PJ. Cleaved cytokeratin-18 is a mechanistically informative biomarker in idiopathic pulmonary fibrosis. Respir Res. 2012;13:105. doi: 10.1186/1465-9921-13-105. PubMed PMID: 23167970; PMCID: PMC3547729.

10. **Lee JS,** Kim EJ, Lynch KL, Elicker B, Ryerson CJ, Katsumoto TR, Shum AK, Wolters PJ, Cerri S, Richeldi L, Jones KD, King TE, Jr., Collard HR. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis. Respir Med. 2013;107(2):249-55. doi: 10.1016/j.rmed.2012.10.018. PubMed PMID: 23186614; PMCID: PMC3543473.

11. Ryerson CJ, Hartman T, Elicker BM, Ley B, **Lee JS,** Abbritti M, Jones KD, King TE, Jr., Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144(1):234-40. doi: 10.1378/chest.12-2403. PubMed PMID: 23370641.

12. **Lee JS,** Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, Yow E, Raghu G, Investigators IP. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. The Lancet Respiratory medicine. 2013;1(5):369-76. doi: 10.1016/S2213-2600(13)70105-X. PubMed PMID: 24429201; PMCID: PMC4059609.

13. Ryerson CJ, Urbania TH, Richeldi L, Mooney JJ, **Lee JS**, Jones KD, Elicker BM, Koth LL, King TE, Jr., Wolters PJ, Collard HR. Prevalence and prognosis of unclassifiable interstitial lung disease. Eur Respir J. 2013;42(3):750-7. doi: 10.1183/09031936.00131912. PubMed PMID: 23222877.

14. Assayag D, Elicker BM, Urbania TH, Colby TV, Kang BH, Ryu JH, King TE, Collard HR, Kim DS, **Lee JS.** Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern. Radiology. 2014;270(2):583-8. doi: 10.1148/radiol.13130187. PubMed PMID: 24126367; PMCID: PMC4228744.

15. Ryerson CJ, Vittinghoff E, Ley B, **Lee JS,** Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Jr., Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014;145(4):723-8. doi: 10.1378/chest.13-1474. PubMed PMID: 24114524.

16. Assayag D, Lubin M, **Lee JS,** King TE, Collard HR, Ryerson CJ. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease. Respirology. 2014;19(4):493-500. doi: 10.1111/resp.12234. PubMed PMID: 24372981.

17. Murray LA, Zhang H, Oak SR, Coelho AL, Herath A, Flaherty KR, **Lee J,** Bell M, Knight DA, Martinez FJ, Sleeman MA, Herzog EL, Hogaboam CM. Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. Am J Respir Cell Mol Biol. 2014;50(5):985-94. doi: 10.1165/rcmb.2013-0342OC. PubMed PMID: 24325475; PMCID: PMC4068948.

18. Lubin M, Chen H, Elicker B, Jones KD, Collard HR, **Lee JS.** A comparison of health-related quality of life in idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Chest. 2014;145(6):1333-8. doi: 10.1378/chest.13-1984. PubMed PMID: 24458311; PMCID: PMC4042514.

19. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, **Lee JS,** Jones KD, Richeldi L, King TE, Jr., Collard HR. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014;273(2):570-9. doi: 10.1148/radiol.14130216. PubMed PMID: 24927326; PMCID: PMC4334234.

20. Stuart BD, **Lee JS\*,** Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Kaza V, Girod CE, Jones KD, Elicker BM, Ma SF, Vij R, Collard HR, Wolters PJ, Garcia CK. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. The Lancet Respiratory medicine. 2014;2(7):557-65. doi: 10.1016/S2213-2600(14)70124-9. PubMed PMID: 24948432; PMCID: PMC4136521. \*Co-first author

21. Tokman S, Singer JP, Devine MS, Westall GP, Aubert JD, Tamm M, Snell GI, **Lee JS,** Goldberg HJ, Kukreja J, Golden JA, Leard LE, Garcia CK, Hays SR. Clinical outcomes of lung transplant recipients with telomerase mutations. J Heart Lung Transplant. 2015;34(10):1318-24. doi: 10.1016/j.healun.2015.05.002. PubMed PMID: 26169663; PMCID: PMC5382798.

22. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE, Jr., Koth LL, **Lee JS**, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109(8):1058-62. doi: 10.1016/j.rmed.2015.06.012. PubMed PMID: 26140806; PMCID: PMC4522344.

23. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, **Lee JS\*,** Leslie KO, Lynch DA, Matteson EL, Mosca M, Noth I, Richeldi L, Strek ME, Swigris JJ, Wells AU, West SG, Collard HR, Cottin V, CTD-ILD EATFoUFo. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976-87. doi: 10.1183/13993003.00150-2015. PubMed PMID: 26160873. \*Writing group member.

24. Assayag D, Kim EJ, Elicker BM, Jones KD, Golden JA, King TE, Jr., Koth LL, Shum AK, Wolters PJ, Collard HR, **Lee JS.** Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria. Respir Med. 2015;109(10):1326-31. doi: 10.1016/j.rmed.2015.08.010. PubMed PMID: 26303338.

25. Morisset J, Dube BP, Garvey C, Bourbeau J, Collard HR, Swigris JJ, **Lee JS.** The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation. Ann Am Thorac Soc. 2016;13(7):1026-33. doi: 10.1513/AnnalsATS.201512-836OC. PubMed PMID: 27064659.

26. Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE, Jr., Koth LL, **Lee JS,** Ley B, Wolters PJ, Collard HR. A diagnostic model for chronic hypersensitivity pneumonitis. Thorax. 2016;71(10):951-4. doi: 10.1136/thoraxjnl-2016-208286. PubMed PMID: 27245779; PMCID: PMC5530732.

27. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, **Lee JS\*,** Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. Am J Respir Crit Care Med. 2016;194(3):265-75. doi: 10.1164/rccm.201604-0801CI. PubMed PMID: 27299520. \*Writing group leader.

28. Chartrand S, Swigris JJ, Stanchev L, **Lee JS,** Brown KK, Fischer A. Clinical features and natural history of interstitial pneumonia with autoimmune features: A single center experience. Respir Med. 2016;119:150-4. doi: 10.1016/j.rmed.2016.09.002. PubMed PMID: 27692137.

29. Wang P, Jones KD, Urisman A, Elicker BM, Urbania T, Johannson KA, Assayag D, **Lee JS,** Wolters PJ, Collard HR, Koth LL. Pathologic Findings and Prognosis in a Large Prospective Cohort of Chronic Hypersensitivity Pneumonitis. Chest. 2017;152(3):502-9. doi: 10.1016/j.chest.2017.02.011. PubMed PMID: 28223152.

30. Johannson KA, Vittinghoff E, Morisset J, **Lee JS,** Balmes JR, Collard HR. Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosis. Eur Respir J. 2017;50(1). doi: 10.1183/13993003.02406-2016. PubMed PMID: 28679608.

31. Natalini JG, Swigris JJ, Morisset J, Elicker BM, Jones KD, Fischer A, Collard HR, **Lee JS.** Understanding the determinants of health-related quality of life in rheumatoid arthritis-associated interstitial lung disease. Respir Med. 2017;127:1-6. doi: 10.1016/j.rmed.2017.04.002. PubMed PMID: 28502413; PMCID: PMC5486989.

32. Ryerson CJ, Corte TJ, **Lee JS\*,** Richeldi L, Walsh SLF, Myers JL, Behr J, Cottin V, Danoff SK, Flaherty KR, Lederer DJ, Lynch DA, Martinez FJ, Raghu G, Travis WD, Udwadia Z, Wells AU, Collard HR. A Standardized Diagnostic Ontology for Fibrotic Interstitial Lung Disease: An International Working Group Perspective. Am J Respir Crit Care Med. 2017. doi: 10.1164/rccm.201702-0400PP. PubMed PMID: 28414524. \*Writing group member

33. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE, Jr., Kim DS, Collard HR, **Lee JS.** The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med. 2017;127:51-6. doi: 10.1016/j.rmed.2017.04.012. PubMed PMID: 28502419; PMCID: PMC5506836.

34. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE, Jr., Collard HR, **Lee JS.** Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Chest. 2017. doi: 10.1016/j.chest.2017.06.009. PubMed PMID: 28629914.

35. Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B, **Collaborators HPD\***. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. Am J Respir Crit Care Med. 2018;197(8):1036-44. Epub 2017/11/28. doi: 10.1164/rccm.201710-1986OC. PubMed PMID: 29172641; PMCID: PMC6839923.

\* HP Delphi collaborator

36. Han MK, Arteaga-Solis E, Blenis J, Bourjeily G, Clegg DJ, DeMeo D, Duffy J, Gaston B, Heller NM, Hemnes A, Henske EP, Jain R, Lahm T, Lancaster LH, **Lee JS**, Legato MJ, McKee S, Mehra R, Morris A, Prakash YS, Stampfli MR, Gopal-Srivastava R, Laposky AD, Punturieri A, Reineck L, Tigno X, Clayton J. Female Sex and Gender in Lung/Sleep Health and Disease: Increased Understanding of Basic Biological, Pathophysiological and Behavioral Mechanisms Leading to Better Health for Female Patients with Lung Disease. Am J Respir Crit Care Med. 2018. doi: 10.1164/rccm.201801-0168WS. PubMed PMID: 29746147.

37. Martin-Medina A, Lehmann M, Burgy O, Hermann S, Baarsma HA, Wagner DE, De Santis MM, Ciolek F, Hofer TP, Frankenberger M, Aichler M, Lindner M, Gesierich W, Guenther A, Walch A, Coughlan C, Wolters P, **Lee JS**, Behr J, Konigshoff M. Increased Extracellular Vesicles Mediate WNT-5A Signaling in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2018. doi: 10.1164/rccm.201708-1580OC. PubMed PMID: 30044642.

38. Raghu G, Pellegrini CA, Yow E, Flaherty KR, Meyer K, Noth I, Scholand MB, Cello J, Ho LA, Pipavath S, **Lee JS**, Lin J, Maloney J, Martinez FJ, Morrow E, Patti MG, Rogers S, Wolters PJ, Yates R, Anstrom KJ, Collard HR. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. The Lancet Respiratory medicine. 2018. doi: 10.1016/S2213-2600(18)30301-1. PubMed PMID: 30100404.

39. Juge PA\*, **Lee JS\***, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, Gonzalez-Perez MI, Mejia M, Buendia-Roldan I, Falfan-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Liote H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clement A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieude P. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med. 2018. doi: 10.1056/NEJMoa1801562. PubMed PMID: 30345907.

\*Co-first authors.

40. **Lee JS,** Fischer A. POINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? Yes. Chest. 2019;155(2):258-60. doi: 10.1016/j.chest.2018.08.1074. PubMed PMID: 30732687.

41. Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, **Lee JS**, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC. Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities. Arthritis Rheumatol. 2019;71(2):182-95. Epub 2019/01/04. doi: 10.1002/art.40769. PubMed PMID: 30604506.

42. Ryerson CJ, Kolb M, Richeldi L, **Lee JS**, Wachtlin D, Stowasser S, Poletti V. Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage. ERJ Open Res. 2019;5(2). Epub 2019/05/03. doi: 10.1183/23120541.00127-2018. PubMed PMID: 31044139; PMCID: PMC6487272

43. Jhajj A, Gill HP, Hague CJ, Murphy D, Elicker B, Soon J, Sulaiman N, Castillo-Saldana D, Wilcox PG, Dunne J, **Lee JS**, Wolters PJ, Ley B, Jones KD, Morisset J, Ryerson CJ. Pulmonary physiology is poorly associated with radiological extent of disease in systemic sclerosis-associated interstitial lung disease. Eur Respir J. 2019. doi: 10.1183/13993003.02182-2018. PubMed PMID: 30846470.

44. He C, **Lee JS**, Cool CD, Wicklund MP, Fischer A. Development of Autoimmune Interstitial Lung Disease in a Patient with Inclusion Body Myositis. Am J Med. 2019. Epub 2019/07/17. doi: 10.1016/j.amjmed.2019.06.023. PubMed PMID: 31310746.

45. Chartrand S, **Lee JS**, Swigris JJ, Stanchev L, Fischer A. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung. 2019;197(6):709-13. Epub 2019/10/05. doi: 10.1007/s00408-019-00276-7. PubMed PMID: 31583453.

46. Greiffo FR, Viteri-Alvarez V, Frankenberger M, Dietel D, Ortega-Gomez A, **Lee JS**, Hilgendorff A, Behr J, Soehnlein O, Eickelberg O, Fernandez IE. CX3CR1-fractalkine axis drives kinetic changes of monocytes in fibrotic interstitial lung diseases. Eur Respir J. 2019. Epub 2019/11/21. doi: 10.1183/13993003.00460-2019. PubMed PMID: 31744836.

47. Moore C, Blumhagen RZ, Yang IV, Walts A, Powers J, Walker T, Bishop M, Russell P, Vestal B, Cardwell J, Markin CR, Mathai SK, Schwarz MI, Steele MP, **Lee J**, Brown KK, Loyd JE, Crapo JD, Silverman EK, Cho MH, James JA, Guthridge JM, Cogan JD, Kropski JA, Swigris JJ, Bair C, Kim DS, Ji W, Kim H, Song JW, Maier LA, Pacheco KA, Hirani N, Poon AS, Li F, Jenkins RG, Braybrooke R, Saini G, Maher TM, Molyneaux PL, Saunders P, Zhang Y, Gibson KF, Kass DJ, Rojas M, Sembrat J, Wolters PJ, Collard HR, Sundy JS, O'Riordan T, Strek ME, Noth I, Ma SF, Porteous MK, Kreider ME, Patel NB, Inoue Y, Hirose M, Arai T, Akagawa S, Eickelberg O, Fernandez IE, Behr J, Mogulkoc N, Corte TJ, Glaspole I, Tomassetti S, Ravaglia C, Poletti V, Crestani B, Borie R, Kannengiesser C, Parfrey H, Fiddler C, Rassl D, Molina-Molina M, Machahua C, Worboys AM, Gudmundsson G, Isaksson HJ, Lederer DJ, Podolanczuk AJ, Montesi SB, Bendstrup E, Danchel V, Selman M, Pardo A, Henry MT, Keane MP, Doran P, Vasakova M, Sterclova M, Ryerson CJ, Wilcox PG, Okamoto T, Furusawa H, Miyazaki Y, Laurent G, Baltic S, Prele C, Moodley Y, Shea BS, Ohta K, Suzukawa M, Narumoto O, Nathan SD, Venuto DC, Woldehanna ML, Kokturk N, de Andrade JA, Luckhardt T, Kulkarni T, Bonella F, Donnelly SC, McElroy A, Armstong ME, Aranda A, Carbone RG, Puppo F, Beckman KB, Nickerson DA, Fingerlin TE, Schwartz DA. Resequencing Study Confirms That Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019;200(2):199-208. Epub 2019/04/30. doi: 10.1164/rccm.201810-1891OC. PubMed PMID: 31034279; PMCID: PMC6635791.

48. Zaman T, Moua T, Vittinghoff E, Ryu JH, Collard HR, **Lee JS**. Differences in Clinical Characteristics and Outcomes Between Men and Women With Idiopathic Pulmonary Fibrosis: A Multicenter Retrospective Cohort Study. Chest. 2020. Epub 2020/02/23. doi: 10.1016/j.chest.2020.02.009. PubMed PMID: 32084394.

49. Furusawa H, Cardwell JH, Okamoto T, Walts AD, Konigsberg IR, Kurche JS, Bang TJ, Schwarz MI, Brown KK, Kropski JA, Rojas M, Cool CD, **Lee JS**, Wolters PJ, Yang IV, Schwartz DA. Chronic Hypersensitivity Pneumonitis, an Interstitial Lung Disease with Distinct Molecular Signatures. Am J Respir Crit Care Med. 2020. Epub 2020/07/01. doi: 10.1164/rccm.202001-0134OC. PubMed PMID: 32602730.

50. Juge PA\*, **Lee JS\***, Lau J\*, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, Koduri G, Matteson E, Bonfiglioli K, Sawamura M, Kairalla R, Cavagna L, Bozzalla Cassione E, Manfredi A, Mejia M, Rodriguez-Henriquez P, Gonzalez-Perez MI, Falfan-Valencia R, Buendia-Roldan I, Perez-Rubio G, Ebstein E, Gazal S, Borie R, Ottaviani S, Kannengiesser C, Wallaert B, Uzunhan Y, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Wemeau-Stervinou L, Flipo RM, Marchand-Adam S, Richette P, Allanore Y, Dromer C, Truchetet ME, Richez C, Schaeverbeke T, Liote H, Thabut G, Deane KD, Solomon J, Doyle T, Ryu JH, Rosas I, Holers VM, Boileau C, Debray MP, Porcher R, Schwartz DA, Vassallo R, Crestani B, Dieude P. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2020. Epub 2020/07/11. doi: 10.1183/13993003.00337-2020. PubMed PMID: 32646919.

\*Co-first authors

51. Dugger DT, Fung M, Hays SR, Singer JP, Ellen Kleinhenz M, Leard LE, Golden JA, Shah RJ, **Lee JS**, Deiter F, Greenland NY, Jones KD, Langelier CR, Greenland JR. Chronic Lung Allograft Dysfunction Small Airways Reveal A Lymphocytic Inflammation Gene Signature. Am J Transplant. 2020. Epub 2020/09/05. doi: 10.1111/ajt.16293. PubMed PMID: 32885581.

52. Graney BA, He C, Marll M, Matson S, Bianchi P, Cosgrove GP, **Lee JS**, Collaborators PCD. Essential Components of an Interstitial Lung Disease Clinic: Results From a Delphi Survey and Patient Focus Group Analysis. Chest. 2020. Epub 2020/10/09. doi: 10.1016/j.chest.2020.09.256. PubMed PMID: 33031832; PMCID: PMC7534733.

53. Iasella CJ, Hoji A, Popescu I, Wei J, Snyder ME, Zhang Y, Xu W, Iouchmanov V, Koshy R, Brown M, Fung M, Langelier C, Lendermon EA, Dugger D, Shah R, **Lee J**, Johnson B, Golden J, Leard LE, Ellen Kleinhenz M, Kilaru S, Hays SR, Singer JP, Sanchez PG, Morrell MR, Pilewski JM, Greenland JR, Chen K, McDyer JF. Type-1 immunity and endogenous immune regulators predominate in the airway transcriptome during chronic lung allograft dysfunction. Am J Transplant. 2020. Epub 2020/10/21. doi: 10.1111/ajt.16360. PubMed PMID: 33078555.

54. Kreuter M, **Lee JS**, Tzouvelekis A, Oldham JM, Molyneaux PL, Weycker D, Atwood M, Kirchgaessler KU, Maher TM. Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2021. Epub 2021/01/13. doi: 10.1164/rccm.202003-0669OC. PubMed PMID: 33434107.

55. **Lee JS**, La J, Aziz S, Dobrinskikh E, Brownell R, Jones KD, Achtar-Zadeh N, Green G, Elicker BM, Golden JA, Matthay MA, Kukreja J, Schwartz DA, Wolters PJ. Molecular Markers of Telomere Dysfunction and Senescence are Common Findings in the Usual Interstitial Pneumonia Pattern of Lung Fibrosis. Histopathology. 2021. Epub 2021/01/13. doi: 10.1111/his.14334. PubMed PMID: 33432658.

56. Kaul B, **Lee JS**, Zhang N, Vittinghoff E, Sarmiento K, Collard HR, Whooley MA. Epidemiology of Idiopathic Pulmonary Fibrosis Among U.S. Veterans, 2010 - 2019. Ann Am Thorac Soc. 2021. Epub 2021/07/28. doi: 10.1513/AnnalsATS.202103-295OC. PubMed PMID: 34314645.

57. Matson SM, Lee SJ, Peterson RA, Achtar-Zadeh NA, Boin F, Wolters PJ, **Lee JS**. The prognostic role of matrix metalloproteinase-7 in scleroderma-associated interstitial lung disease. Eur Respir J. 2021;58(6). Epub 2021/10/01. doi: 10.1183/13993003.01560-2021. PubMed PMID: 34588190.

58. Aronson KI, Danoff SK, Russell AM, Ryerson CJ, Suzuki A, Wijsenbeek MS, Bajwah S, Bianchi P, Corte TJ, **Lee JS**, Lindell KO, Maher TM, Martinez FJ, Meek PM, Raghu G, Rouland G, Rudell R, Safford MM, Sheth JS, Swigris JJ. Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2021;204(2):e3-e23. Epub 2021/07/21. doi: 10.1164/rccm.202105-1193ST. PubMed PMID: 34283696; PMCID: PMC8650796.

59. Juge PA, Solomon JJ, van Moorsel CHM, Garofoli R, **Lee JS**, Louis-Sydney F, Rojas-Serrano J, Gonzalez-Perez MI, Mejia M, Buendia-Roldan I, Falfan-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou KM, Sidiropoulos P, Trachalaki A, van der Vis JJ, Jamnitski A, Grutters JC, Kannengiesser C, Borie R, Kawano-Dourado L, Wemeau-Stervinou L, Flipo RM, Nunes H, Uzunhan Y, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Richez C, Schaeverbeke T, Doyle T, Wolters PJ, Debray MP, Boileau C, Porcher R, Schwartz DA, Crestani B, Dieude P. MUC5B promoter variant rs35705950 and rheumatoid arthritis associated interstitial lung disease survival and progression. Semin Arthritis Rheum. 2021;51(5):996-1004. Epub 2021/08/20. doi: 10.1016/j.semarthrit.2021.07.002. PubMed PMID: 34411838

60. Matson SM, Deane KD, Peljto AL, Bang TJ, Sachs PB, Walts AD, Collora C, Ye S, Demoruelle MK, Humphries SM, Schwartz DA, **Lee JS**. Prospective Identification of Subclinical Interstitial Lung Disease in Rheumatoid Arthritis Cohort is Associated with the MUC5B Promoter Variant. Am J Respir Crit Care Med. 2021. Epub 2021/12/08. doi: 10.1164/rccm.202109-2087LE. PubMed PMID: 34874815.

61. Torrisi SE, Kahn N, Walscher J, Polke M, **Lee JS**, Molyneaux PL, Sambataro FM, Heussel CP, Vancheri C, Kreuter M. Outcomes and Incidence of PF-ILD According to Different Definitions in a Real-World Setting. Front Pharmacol. 2021;12:790204. Epub 2022/01/04. doi: 10.3389/fphar.2021.790204. PubMed PMID: 34975486; PMCID: PMC8718675.

62. Furusawa H, Peljto AL, Walts AD, Cardwell J, Molyneaux PL, **Lee JS,** Fernandez Perez ER, Wolters PJ, Yang IV, Schwartz DA. Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis. Thorax. 2022. Epub 2022/01/09. doi: 10.1136/thoraxjnl-2021-217693. PubMed PMID: 34996848.

63. Rahaghi FF, Kolaitis NA, Adegunsoye A, de Andrade J, Flaherty KR, Lancaster L, **Lee JS**, Levine D, Preston IR, Safdar Z, Saggar R, Sahay S, Scholand MB, Shlobin O, Zisman DA, Nathan SD. Screening Strategies for Pulmonary Hypertension in Patients with Interstitial Lung Disease: A Multidisciplinary Delphi Study. Chest. 2022. Epub 2022/02/18. doi: 10.1016/j.chest.2022.02.012. PubMed PMID: 35176276.

64. Kaul B, **Lee JS,** Glidden D, Blanc PD, Zhang N, Collard HR, Whooley MA. Agent Orange Exposure and Risk of Idiopathic Pulmonary Fibrosis Among U.S. Veterans. Am J Respir Crit Care Med. 2022. Epub 2022/05/14. doi: 10.1164/rccm.202112-2724OC. PubMed PMID: 35559726.

65. Cottin V, Tomassetti S, Valenzuela C, Walsh S, Antoniou K, Bonella F, Brown KK, Collard HR, Corte TJ, Flaherty K, Johannson KA, Kolb M, Kreuter M, Inoue Y, Jenkins G, **Lee JS**, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers J, Nathan SD, Poletti V, Quadrelli S, Raghu G, Rajan SK, Ravaglia C, Remy-Jardin M, Renzoni E, Richeldi L, Spagnolo P, Troy L, Wijsenbeek M, Wilson KC, Wuyts W, Wells AU, Ryerson C. Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. Am J Respir Crit Care Med. 2022. Epub 2022/03/31. doi: 10.1164/rccm.202111-2607PP. PubMed PMID: 35353660.

**Peer-reviewed Review Articles (chronological order):**

1. **Lee JS**, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE, Jr. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med. 2010;123(4):304-11. doi: 10.1016/j.amjmed.2009.07.033. PubMed PMID: 20362747; PMCID: PMC2851633.

2. **Lee JS,** McLaughlin S, Collard HR. Comprehensive care of the patient with idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2011;17(5):348-54. doi: 10.1097/MCP.0b013e328349721b. PubMed PMID: 21760508.

3. Doyle TJ, **Lee JS\*,** Dellaripa PF, Lederer JA, Matteson EL, Fischer A, Ascherman DP, Glassberg MK, Ryu JH, Danoff SK, Brown KK, Collard HR, Rosas IO. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest. 2014;145(3):454-63. doi: 10.1378/chest.13-2408. PubMed PMID: 24590021; PMCID: PMC3941243. \*Co-first authors.

4. **Lee JS.** The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis. Clinical pulmonary medicine. 2014;21(2):81-5. PubMed PMID: 24729673; PMCID: PMC3979481.

5. Assayag D, **Lee JS,** King TE, Jr. Rheumatoid arthritis associated interstitial lung disease: a review. Medicina (B Aires). 2014;74(2):158-65. PubMed PMID: 24736263.

6. Hu X, **Lee JS,** Pianosi PT, Ryu JH. Aspiration-related pulmonary syndromes. Chest. 2015;147(3):815-23. doi: 10.1378/chest.14-1049. PubMed PMID: 25732447.

7. de Boer K, **Lee JS.** Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review. Respirology. 2016;21(6):995-1004. doi: 10.1111/resp.12622. PubMed PMID: 26365251.

8. Fischer A, **Lee JS,** Cottin V. Interstitial lung disease evaluation: detecting connective tissue disease. Respiration. 2015;90(3):177-84. doi: 10.1159/000440665. PubMed PMID: 26343272.

9. **Lee JS,** Collard HR. Idiopathic pulmonary fibrosis: continuing to make progress. The Lancet Respiratory medicine. 2015;3(12):921-3. doi: 10.1016/S2213-2600(15)00469-5. PubMed PMID: 26679021.

10. Aparicio IJ, **Lee JS.** Connective Tissue Disease-Associated Interstitial Lung Diseases: Unresolved Issues. Semin Respir Crit Care Med. 2016;37(3):468-76. doi: 10.1055/s-0036-1580689. PubMed PMID: 27231868.

11. Morisset J, Johnson C, Rich E, Collard HR, **Lee JS.** Management of Myositis-Related Interstitial Lung Disease. Chest. 2016;150(5):1118-28. doi: 10.1016/j.chest.2016.04.007. PubMed PMID: 27102182.

12. **Lee JS,** Fischer A. Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease. Expert Rev Clin Immunol. 2016;12(5):509-20. doi: 10.1586/1744666X.2016.1139454. PubMed PMID: 26752397.

13. Spagnolo P, Oldham JM, Jones MG, **Lee JS.** Personalized medicine in interstitial lung diseases. Curr Opin Pulm Med. 2017;23(3):231-6. doi: 10.1097/MCP.0000000000000370. PubMed PMID: 28198728.

14. Spagnolo P, **Lee JS,** Sverzellati N, Rossi G, Cottin V. The lung in rheumatoid arthritis - focus on interstitial lung disease. Arthritis Rheumatol. 2018. doi: 10.1002/art.40574. PubMed PMID: 29806092.

15. Graney BA, **Lee JS.** Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. Patient Relat Outcome Meas. 2018;9:321-8. doi: 10.2147/PROM.S144425. PubMed PMID: 30288134; PMCID: PMC6163010.

16. Mira-Avendano I, Abril A, Burger CD, Dellaripa PF, Fischer A, Gotway MB, Lee AS, **Lee JS**, Matteson EL, Yi ES, Ryu JH. Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clin Proc. 2018. Epub 2018/12/19. doi: 10.1016/j.mayocp.2018.09.002. PubMed PMID: 30558827.

17. Morisset J, **Lee JS**. New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern? Curr Opin Pulm Med. 2019. Epub 2019/07/02. doi: 10.1097/MCP.0000000000000600. PubMed PMID: 31261211.

18. Zaman T, **Lee JS**. Risk factors for the development of idiopathic pulmonary fibrosis: A review. Curr Pulmonol Rep. 2018;7(4):118-25. Epub 2019/10/08. doi: 10.1007/s13665-018-0210-7. PubMed PMID: 31588408; PMCID: PMC6777743.

19. Lee AS, **Lee JS**, He Z, Ryu JH. Reflux-Aspiration in Chronic Lung Disease. Ann Am Thorac Soc. 2019. Epub 2019/11/08. doi: 10.1513/AnnalsATS.201906-427CME. PubMed PMID: 31697575.

20. Spagnolo P, Distler O, Ryerson CJ, Tzouvelekis A, **Lee JS**, Bonella F, Bouros D, Hoffmann-Vold AM, Crestani B, Matteson EL. Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs). Ann Rheum Dis. 2021;80(2):143-50. Epub 2020/10/11. doi: 10.1136/annrheumdis-2020-217230. PubMed PMID: 33037004.

21. Matson S, **Lee J**, Eickelberg O. Two sides of the same coin? A review of the similarities and differences between idiopathic pulmonary fibrosis and rheumatoid arthritis associated interstitial lung disease. Eur Respir J. 2020. Epub 2020/12/12. doi: 10.1183/13993003.02533-2020. PubMed PMID: 33303554.

22. Spagnolo P, Kropski JA, Jones MG, **Lee JS**, Rossi G, Karampitsakos T, Maher TM, Tzouvelekis A, Ryerson CJ. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. Pharmacol Ther. 2020;222:107798. Epub 2020/12/29. doi: 10.1016/j.pharmthera.2020.107798. PubMed PMID: 33359599.

23. Kawano-Dourado L, **Lee JS**. Management of Connective Tissue Disease-Associated Interstitial Lung Disease. Clin Chest Med. 2021;42(2):295-310. Epub 2021/05/25. doi: 10.1016/j.ccm.2021.03.010. PubMed PMID: 34024405

24. King TE, Jr., **Lee JS**. Cryptogenic Organizing Pneumonia. N Engl J Med. 2022;386(11):1058-69. Epub 2022/03/17. doi: 10.1056/NEJMra2116777. PubMed PMID: 35294814.

**Books/Section Editor Roles**

1. Lung Disease in Rheumatoid Arthritis. Springer. Editors Fischer, A and **Lee, J.S.** 2018. Springer Nature. ISBN 9783319688879.
2. Encyclopedia of Respiratory Medicine, Second Edition. 2022. **Lee, J.S.** Section Editor, Interstitial Lung Disease in Respiratory Medicine. Elsevier. ISBN 978-0-08-102724-0
3. UpToDate. **Lee, J.S.** Section Editor, Interstitial Lung Disease.

**Book Chapters (chronological order):**

1. **Lee, J.S**., Golden, J.A. Interstitial Lung Disease,in PocketMedicine/Internal Medicine, Version 3.0 (2010), A Textbook of Internal Medicine for the Handheld Platform, Stephen C. Lazarus, Associate Editor. PocketMedicine.com, Inc.  New York, NY. (book chapter)
2. **Lee, J.S.,** Collard, H.R. Acute Exacerbation of Idiopathic Pulmonary Fibrosis, in Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide, Meyer K.C. and Nathan, S.D. Editors. Respiratory Medicine. ISBN 978-1-62703-681-8. 2013 (book chapter)
3. **Lee, J.S.** Overview of Interstitial Lung Diseases. The Merck Manuals. 2016-2018. Kenilworth, NJ. <http://www.merckmanuals.com/professional/pulmonary-disorders/interstitial-lung-diseases/overview-of-interstitial-lung-disease> (book chapter, updated yearly).
4. **Lee, JS,** Fontenot AP.  Immunologic Lung Disease.  In: Clinical Immunology: Practices and Principles. Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, Editors. 2017, 5th Edition, Elsevier. ISBN 9780702068966. (book chapter)
5. de Boer, K., **Lee, J.S.** Clinical Evaluation of the Patient with Suspected ILD. The CRC Press Clinical Handbook of Interstitial Lung Disease. Thillai M., Moller D., and Meyer K.C., Editors. 2017. CRC Press. ISBN 9781498768252. (book chapter)
6. Morisset, J., **Lee, J.S**. Rheumatoid Arthritis Associated Interstitial Lung Disease. Lung Disease in Rheumatoid Arthritis. Fischer, A. and **Lee, J.S.,** Editors. 2018. Springer Nature. ISBN 9783319688879. (book chapter)
7. **Lee, J.S.,** Collard, H.R. Acute Exacerbation of Idiopathic Pulmonary Fibrosis, in Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide, Meyer K.C. and Nathan, S.D. Editors. Respiratory Medicine. ISBN 9783319999746. 2018 (book chapter)
8. **Lee, J.S.** Gastroesophageal Reflux and IPF, in Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide, Meyer K.C. and Nathan, S.D. Editors. Respiratory Medicine. ISBN 9783319999746. 2018 (book chapter)
9. **Lee, J.S.** Overview of Interstitial Lung Diseases. The Merck Manuals. 2019-2022. Kenilworth, NJ. <http://www.merckmanuals.com/professional/pulmonary-disorders/interstitial-lung-diseases/overview-of-interstitial-lung-disease> (book chapter, updated yearly).
10. **Lee, J.S.** Diffuse Alveolar Hemorrhage and Pulmonary Renal Syndrome. The Merck Manuals. 2019-2022. Kenilworth, NJ. <https://www.merckmanuals.com/professional/pulmonary-disorders/diffuse-alveolar-hemorrhage-and-pulmonary-renal-syndrome/diffuse-alveolar-hemorrhage> (book chapter, updated yearly)
11. Matson, S, **Lee, JS,** Fontenot AP.  Immunologic Lung Disease.  In: Clinical Immunology: Practices and Principles. Rich RR, Fleisher TA, Shearer WT, Schroeder HW, Frew AJ, Weyand CM, Editors. 2020, 6th Edition, Elsevier. ISBN [9780702081651](https://isbnsearch.org/isbn/9780702081651). (book chapter)
12. Ryu, J.H., Selman, M., **Lee, J.S.,** Colby, T.V., King, T.E. Idiopathic Pulmonary Fibrosis. Murray & Nadel’s Textbook of Respiratory Medicine, 7th Edition. 2021. ISBN [9780323655873](https://isbnsearch.org/isbn/9780323655873) (book chapter)
13. Graney, B.A., **Lee, J.S.,** King, T.E. Nonspecific Interstitial Pneumonitis and Other Idiopathic Interstitial Pneumonias. Murray & Nadel’s Textbook of Respiratory Medicine, 7th Edition. 2021. ISBN [9780323655873](https://isbnsearch.org/isbn/9780323655873) (book chapter)
14. Matson, S., **Lee, J.S**. Rheumatoid Arthritis Associated Interstitial Lung Disease. Encyclopedia of Respiratory Medicine, Second Edition. 2021. ISBN 978-0-08-102724-0 (book chapter)

**Other (chronological order):**

1. Matthay MA, **Lee J.** Beta2 adrenergic agonist therapy may enhance alveolar epithelial repair in patients with acute lung injury. Thorax. 2008;63(3):189-90. doi: 10.1136/thx.2007.086256. PubMed PMID: 18308954. (invited editorial)

2. **Lee JS,** Collard HR. Primum non nocere: safety in clinical trials for IPF. Respirology. 2011;16(5):723-4. doi: 10.1111/j.1440-1843.2011.01971.x. PubMed PMID: 21426439. (invited editorial)

3. Johannson KA, de Boer K, Wolters PJ, Golden JA, **Lee JS,** Collard HR. Diagnosis of idiopathic pulmonary fibrosis with high-resolution CT. The Lancet Respiratory medicine. 2014;2(5):e5. doi: 10.1016/S2213-2600(14)70075-X. PubMed PMID: 24815808. (letter to the editor)

4. **Lee JS.** An Ounce of Prevention... Will This Be the Future for IPF? Am J Respir Crit Care Med. 2017. doi: 10.1164/rccm.201706-1116ED. PubMed PMID: 28628389. (invited editorial)

5. Rangarajan S, **Lee JS**. The TAMing of the Idiopathic Pulmonary Fibrosis Myofibroblast. One Step Closer? Am J Respir Crit Care Med. 2018;197(11):1377-8. doi: 10.1164/rccm.201802-0222ED. PubMed PMID: 29664671. (invited editorial).

6. Matson SM, Griffith M, **Lee JS**. FocuSSced on the Target in Systemic Sclerosis-Interstitial Lung Disease: Another Arrow in the Quiver? Am J Respir Crit Care Med. 2022;205(6):608-10. Epub 2021/12/15. doi: 10.1164/rccm.202111-2587ED. PubMed PMID: 34905698. (invited editorial)

7. Wijsenbeek M, **Lee JS**, Udwadia Z, Kreuter M. Editorial: Interstitial Lung Disease Around the World. Front Med (Lausanne). 2022;9:865334. Epub 2022/04/05. doi: 10.3389/fmed.2022.865334. PubMed PMID: 35372425; PMCID: PMC8971624. (invited editorial)

**Published Abstracts (reverse chronological order, first and last author only):**

1. **Lee, J.S.,** Boente, R, White, E., Baxter, C., Shore, J.E., Collard, H.R. Differences in Patient Outcomes Across the PFF Care Center Network. Am J Respir Crit Care Med; 2022
2. C. He, B.A. Graney, S. Matson, P. Bianchi, G.P. Cosgrove, **J.S. Lee**. A Survey of Interstitial Lung Disease Clinics in the Pulmonary Fibrosis Foundation Care Center Network. Am J Respir Crit Care Med; 2020; 201; A3355
3. S. Matson, J. Cardwell, I.V. Yang, K. Deane, J.H. Ryu, E. Matteson, P.J. Wolters, D.A. Schwartz, **J.S. Lee**. Circulating Protein Biomarkers in Rheumatoid Arthritis Associated Interstitial Lung disease. Am J Respir Crit Care Med; 2020; 201; A1094
4. T. Zaman, H.R. Collard, **J.S. Lee**. Sex-Specific Predictors of Death in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med; 2018; 197:A1607
5. **Lee, J.S.,** Deane, K., Walts, A.D., Fingerlin T., Fischer, A., Ryu, J., Matteson, E.L., Niewold, T., Assayag, D., Wolters, P, Collard, H., Schwarz, M.I., Holers, M., Schwartz, D.A. The MUC5B Promoter Variant is Associated with Rheumatoid Arthritis Associated Interstitial Lung Disease. Am J Respir Crit Care Med; 2017; 195: A2456
6. **Lee, J.S.,** Ley, B., Hennessy, C., Estrella, A., Walts, A.D., Schwarz, M.I., Wolters, P.J., Collard, H.R., Yang, I.V., Schwartz, D.A. Idiopathic pulmonary fibrosis and the MUC5B promoter variant rs35705950 are associated with elevated concentrations of MUC5B in bronchoalveolar lavage fluid. Am J Respir Crit Care Med; 2017; 195: A6793.
7. Post, J.M., Bang, T.J., Meadows, C., Fischer, A., Bull, T.M., **Lee, J.S.** Understanding the pulmonary phenotypes of patients with systemic sclerosis. Am J Respir Crit Care Med; 2017; 195: A1582
8. **Lee, J.S.,** Keith, R., Meadows, C., Fischer, A., Bull, T. Differential expression of proteins in Scleroderma Patients with and without interstitial lung disease. Am J Respir Crit Care Med; 2016: A1550.
9. Morisset, J., Dube, B.P., Garvey, C., Bourbeau, J., Collard, H.R., Swigris, J.J., **Lee, J.S.** The unmet educational needs of interstitial lung disease patients: setting the stage for tailored pulmonary rehabilitation. Am J Respir Crit Care Med; 2016. A4519.
10. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KJ, Cerri S, Manfredi A, Sebastiani M, Ley B, Wolters PJ, King TE, Kim DS, Collard HR, **Lee JS.** Predicting Mortality in Patients with Rheumatoid Arthritis Related Interstitial Lung Disease: Expanding The GAP Model. Am J Respir Crit Care Med; 2016: A4288
11. Morisset J, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Ley B, Wolters PJ, King TE, Collard HR, **Lee JS.** Predictors of mortality and risk prediction among patients with scleroderma related interstitial lung disease. European Respiratory Journal2015; 46.
12. **Lee, J.S**., Wolters, P.J., Cello, J.P., Golden, J., Aziz, S., Jones, K.D., Rogers, S., Matthay, M.A., King, T.E., Collard, H.R. Bronchoalveolar lavage pepsin levels are significantly elevated in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 191; 2015: A2516. Poster Discussion Session ATS 2015, Denver, CO.
13. Assayag, D., Kim. E., Elicker, B.M, Golden, J., Jones, K.D., King, T.E., Koth, L.L., Wolters, P.J., Collard, H.R., **Lee, J.S.** Survival in Interstitial Pneumonia with Features of Autoimmune Disease. Am J Respir Crit Care Med 189; 2014: A1484
14. D. Assayag, B. Elicker, T. Urbania, B. Kang, J. Ryu, T. King, H. Collard, D. Kim, **J. Lee.** The Accuracy of Radiologic Usual Interstitial Pneumonia Pattern in Rheumatoid Arthritis Associated Interstitial Lung Disease. Am J Respir Crit Care Med 187; 2013: A1078
15. **J. Lee**, H. Collard, B. Elicker, K. Jones, T. King, P. Wolters, Telomere Length and Survival in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 187; 2013: A5715. Oral Presentation, Philadelphia, PA.
16. Burrell, J. Mooney, J. Ryu, C. Ryerson, B. Elicker, K. Jones, P. Wolters, T. King, L. Koth, H. Collard, **J. Lee.** The Relationship of Body Mass Index To Survival Time in Interstitial Lung Disease. G. Am J Respir Crit Care Med 185; 2012: A4120. Poster Discussion Session, San Francisco, CA.
17. **J. Lee,** E. Kim, K. Lynch, B. Elicker, C. Ryerson, T. Katsumoto, A. Shum, P. Wolters, L. Richeldi, K. Jones, T. King, H. Collard. Clinical Significance of Circulating Autoantibodies in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 185; 2012: A4372. Poster Discussion Session, San Francisco, CA.
18. **Lee, J.S.**, Song, J.W., Wolters, P., Elicker, B., Golden, J.A., King, T.E., Kim, D.S., Collard, H.R. Pepsin Levels in Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 183; 2011: A3804. Poster Discussion Session, Denver, CO.
19. **J.S. Lee, B.M. Elicker, M.P. Sweet, J.A. Golden, T.E. King, Jr., H.R. Collard. Hiatal Hernia Predicts Survival in Patients with Idiopathic Pulmonary Fibrosis. Proc. Am. Thorac Soc. 2009; A1119.** Poster Discussion Session, San Diego, CA.
20. **J.S. Lee,** N. Gupta, X. Su, M.A. Matthay. **Priming with Endotoxin Increases Acute Lung Injury in Mice by Enhancing the Severity of Lung Endothelial Injury.** Proc. Am. Thorac Soc. 2008; 5:A598. Poster Discussion Session, Toronto, ON, Canada
21. **J.S. Lee**, S. Hays, L. Leard, H. Collard, K.D. Jones, C. Hoopes, J. Golden. **Lung Transplantation for Acute Respiratory Failure in Patients with Idiopathic Pulmonary Fibrosis.** Proc. Am. Thorac Soc. 2008; 5:A389.